If tryptase and CD117 were routinely applied in the diagnosis of all cases of advanced myeloid neoplasms, it is estimated that MML would be identified in 3% of myeloid neoplasms [11,39,40]. This evidence concerns the gene KIT and myeloid neoplasm.